Rationale and design of a randomised, controlled, multicenter trial investigating the effects of selective serotonin re‐uptake inhibition on morbidity, mortality and mood in depressed heart failure patients (MOOD‐HF)

[1]  A. Schene,et al.  Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. , 2007, The American journal of psychiatry.

[2]  R. Califf,et al.  Relationship between depressive symptoms and long-term mortality in patients with heart failure. , 2007, American heart journal.

[3]  B. Thombs,et al.  Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. , 2007, The American journal of medicine.

[4]  A. Schene,et al.  Effects of antidepressant treatment following myocardial infarction , 2007, British Journal of Psychiatry.

[5]  Philip Scheltens,et al.  Cognitive impairment in heart failure: A systematic review of the literature , 2007, European journal of heart failure.

[6]  G. Koch,et al.  Relationship of depression to death or hospitalization in patients with heart failure. , 2007, Archives of internal medicine.

[7]  N. Frasure-smith,et al.  Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. , 2007, JAMA.

[8]  Paul J Mills,et al.  Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. , 2006, Journal of the American College of Cardiology.

[9]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[10]  D. Redelmeier,et al.  The risk of suicide with selective serotonin reuptake inhibitors in the elderly. , 2006, The American journal of psychiatry.

[11]  M. Dubé,et al.  Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin , 2006, Psychosomatic medicine.

[12]  R. Lam,et al.  Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. , 2006, Journal of psychiatry & neuroscience : JPN.

[13]  N. Frasure-smith,et al.  Design and Rationale for a Randomized, Controlled Trial of Interpersonal Psychotherapy and Citalopram for Depression in Coronary Artery Disease (CREATE) , 2006, Psychosomatic medicine.

[14]  B. Löwe,et al.  Responsiveness of the PHQ-9 to Psychopharmacological Depression Treatment. , 2006, Psychosomatics.

[15]  A. Schene,et al.  Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. , 2005, European heart journal.

[16]  Henry Krum,et al.  The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). , 2005, European heart journal.

[17]  R. Carney,et al.  Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. , 2005, Archives of general psychiatry.

[18]  D. Moser,et al.  Depression and anxiety in heart failure. , 2005, Journal of cardiac failure.

[19]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[20]  Kenneth E Freedland,et al.  Depression, the Autonomic Nervous System, and Coronary Heart Disease , 2005, Psychosomatic medicine.

[21]  I. Paraskevaidis,et al.  Depression in chronic heart failure: novel pathophysiological mechanisms and therapeutic approaches , 2005, Expert opinion on investigational drugs.

[22]  D. Musselman,et al.  Depression, alterations in platelet function, and ischemic heart disease. , 2005, Psychosomatic medicine.

[23]  J. Gottdiener,et al.  The role of immune system parameters in the relationship between depression and coronary artery disease. , 2005, Psychosomatic medicine.

[24]  J. Spertus,et al.  [The Kansas City Cardiomyopathy Questionnaire (KCCQ) -- a new disease-specific quality of life measure for patients with chronic heart failure]. , 2005, Psychotherapie, Psychosomatik, medizinische Psychologie.

[25]  Karina W Davidson,et al.  The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. , 2005, Journal of the American College of Cardiology.

[26]  B. Löwe,et al.  Detecting and monitoring depression with a two-item questionnaire (PHQ-2). , 2005, Journal of psychosomatic research.

[27]  R. Bagby,et al.  The Hamilton Depression Rating Scale: has the gold standard become a lead weight? , 2004, The American journal of psychiatry.

[28]  C. Herrmann-Lingen,et al.  Depression as a Risk Factor for Mortality in Patients With Coronary Heart Disease: A Meta-analysis , 2004, Psychosomatic medicine.

[29]  J. Tijssen,et al.  Prognostic Association of Depression Following Myocardial Infarction With Mortality and Cardiovascular Events: A Meta-analysis , 2004, Psychosomatic medicine.

[30]  A. Sherwood,et al.  Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. , 2004, Journal of psychosomatic research.

[31]  B. Löwe,et al.  Measuring depression outcome with a brief self-report instrument: sensitivity to change of the Patient Health Questionnaire (PHQ-9). , 2004, Journal of affective disorders.

[32]  R. Dantzer,et al.  Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy , 2004, Brain, Behavior, and Immunity.

[33]  M. Palkovits,et al.  Remodeling of the brain post myocardial infarction: Focus on central ANF , 1997, Basic Research in Cardiology.

[34]  P. Mecocci,et al.  Cognitive impairment: a key feature of congestive heart failure in the elderly , 2003, Journal of Neurology.

[35]  Christopher M O'Connor,et al.  Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy , 2003, Circulation.

[36]  B. Pieske,et al.  High Plasma Levels of N‐Terminal Pro‐Atrial Natriuretic Peptide Associated With Low Anxiety in Severe Heart Failure , 2003, Psychosomatic medicine.

[37]  N. Schneiderman,et al.  Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. , 2003, JAMA.

[38]  J. Spertus,et al.  Depression-related costs in heart failure care. , 2002, Archives of internal medicine.

[39]  R. Califf,et al.  Sertraline treatment of major depression in patients with acute MI or unstable angina , 2002, European Neuropsychopharmacology.

[40]  W. Burke,et al.  Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. , 2002, The Journal of clinical psychiatry.

[41]  C M O'Connor,et al.  Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. , 2001, Archives of internal medicine.

[42]  P. Svanborg,et al.  A comparison between the Beck Depression Inventory (BDI) and the self-rating version of the Montgomery Asberg Depression Rating Scale (MADRS). , 2001, Journal of affective disorders.

[43]  M. Palkovits,et al.  Chronic effects of ACE-inhibition (quinapril) and angiotensin-II type-1 receptor blockade (losartan) on atrial natriuretic peptide in brain nuclei of rats with experimental myocardial infarction , 2001, Basic Research in Cardiology.

[44]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[45]  R Shavelle,et al.  An extended Kaplan-Meier estimator and its applications. , 1998, Statistics in medicine.

[46]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .

[47]  M. Palkovits,et al.  Changes of atrial natriuretic peptide in brain areas of rats with chronic myocardial infarction. , 1996, The American journal of physiology.

[48]  C. Nemeroff,et al.  Exaggerated platelet reactivity in major depression. , 1996, The American journal of psychiatry.

[49]  M. First,et al.  Structured clinical interview for DSM-IV axis I disorders : SCID-I: clinical version : administration booklet , 1996 .

[50]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[51]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[52]  M Bobak,et al.  Alcohol and coronary heart disease. , 1985, The New Zealand medical journal.